# Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/comparative-effectiveness-of-non-cisplatin-first-line-therapies-for-metastatic/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Nancy Vander Velde,Annie Guérin,Raluca Ionescu‐Ittu,Sherry Shi,Eric Q. Wu,Shih‐Wen Lin,Ling‐I Hsu,Kai‐Uwe Saum,Sabine de Ducla,Jingjing Wang,Shi Li,AnnChristine Thåström,Shuqian Liu,Lizheng Shi,John T. Leppert |
| Citations | 22 |
| DOI | 10.1016/j.euo.2018.07.003 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2886065680 |
| PMID | 30929841 |
| Type | article |
| Year | 2018 |

## Paper authors

- [Sherry Shi](https://scholariq.org/researchers/sherry-shi/)

## Paper primary topic

- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)

## Paper topics

- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.